Related Experiment Video
Updated: Mar 28, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor
Tomohiro Osaki1, Cai-Xia Wang1, Taro Tachibana1,2
11 Department of Applied Chemistry and Bioengineering, Graduate School of Engineering, Osaka City University , Sumiyoshi-ku, Osaka, Japan .
Abstract:
Overexpression of the epidermal growth factor receptor (EGFR) gene and dysregulation of EGFR signaling are observed in various cancer cells, and EGFR is a validated target for cancer therapy. In the present study, we report on the generation of two rat anti-EGFR antibodies (clones 2C2D3 and 4H7F4) by using the rat lymph node method. Flow cytometric analysis and immunofluorescence showed that both antibodies specifically bound to EGFR on the surface of cancer cells. Competitive analysis demonstrated that the epitope of each antibody had no overlap with that of the therapeutic anti-EGFR antibody cetuximab. These results suggest that 2C2D3 and 4H7F4 are potentially useful in EGFR-targeted cancer therapy.
Insights
Researchers developed two new rat antibodies, 2C2D3 and 4H7F4, that specifically target the epidermal growth factor receptor (EGFR). These antibodies show potential for use in EGFR-targeted cancer therapies, binding to cancer cells without overlapping cetuximab's epitope.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Epidermal growth factor receptor (EGFR) overexpression and signaling dysregulation are common in various cancers.
- EGFR is a well-established therapeutic target for cancer treatment.
- Developing novel antibodies targeting EGFR is crucial for advancing cancer therapy.
Purpose of the Study:
- To generate and characterize novel rat anti-EGFR antibodies.
- To assess the specificity and binding epitope of the generated antibodies.
- To evaluate the potential utility of these antibodies in EGFR-targeted cancer therapy.
Main Methods:
- Generation of rat anti-EGFR monoclonal antibodies using the rat lymph node method.
- Flow cytometry and immunofluorescence assays to confirm antibody binding to EGFR on cancer cells.
- Competitive binding assays to determine epitope overlap with cetuximab.
Main Results:
- Two rat anti-EGFR antibody clones, 2C2D3 and 4H7F4, were successfully generated.
- Both antibodies demonstrated specific binding to surface-expressed EGFR on cancer cells.
- The binding epitopes of 2C2D3 and 4H7F4 do not overlap with that of cetuximab.
Conclusions:
- The novel rat antibodies 2C2D3 and 4H7F4 specifically target EGFR.
- These antibodies bind to a distinct epitope compared to cetuximab.
- 2C2D3 and 4H7F4 represent promising candidates for developing new EGFR-targeted cancer therapies.
